Open Monoclonal Technology, (OMT), a leader in genetic engineering of animals for discovery of human therapeutic antibodies, announced issuance of US patent application 8,703,485 related to inactivation of rodent immunoglobulin genes and generation of human antibodies. The issuance came with a patent term extension of 1,228 days and will further strengthen the intellectual property of the company’s OmniAb suite of human therapeutic antibody platforms, including OmniRat OmniMouse and OmniFlic.

The issuance follows the grant of European patent numbers EP2152880 and EP2336329 for similar inventions. In addition, OMT has granted patent protection for related technologies in Australia, China, Hong Kong, Israel and New Zealand as well as pending applications in Canada, Japan, and Singapore.

Dr. Roland Buelow, founder and chief executive officer, of OMT, said, “OMT was founded to establish new human therapeutic antibody platforms with freedom to operate in transgenic animals. The initial focus was in rats where the company has platforms for generation of mono- and bispecific antibodies. OMT has also been able to design a mouse system with similar intellectual property benefits. All three platforms are available to OMT’s partners in single licenses, thus offering a convenient and efficient way of creating the optimal antibody format for each scarce therapeutic target, including single antibodies and cocktails as well as naked and drug-conjugated antibodies.”

Open Monoclonal Technology, is a leader in genetic engineering of animals for discovery of human therapeutic antibodies, naturally optimised human antibodies, and the only company in the world with three transgenic animal platforms, OmniAb.